Funder
Pfizer
Moffitt Cancer Center
Novartis
Astellas Pharma US
Merck KGaA
Roche
AstraZeneca
Daiichi-Sankyo
Sanofi
Genentech
Spectrum Pharmaceuticals
Eli Lilly and Company
Takeda Pharmaceuticals U.S.A.
Merck
Amgen
Bristol-Myers Squibb
Boehringer Ingelheim
GlaxoSmithKline
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference37 articles.
1. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584–594.
2. Inoperable stage III non-small cell lung cancer: current treatment and role of vinorelbine;Provencio;J Thorac Dis,2011
3. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007;Walters;Thorax,2013
4. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04;Ahn;J Clin Oncol,2015
5. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Auperin;J Clin Oncol,2010